Physician profile
Mari E Asper
NPI 1073710786
$7,154.30
in general payments reported to CMS, 2019-2025
33 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $275 · 2021: $620 · 2022: $771 · 2023: $1,746 · 2024: $1,546 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,686.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.77 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $679.79 | 2019-2025 | Rexulti |
| Corium, LLC | $649.29 | 2022-2025 | Azstarys |
| Lundbeck LLC | $443.38 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $424.61 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $408.73 | 2023-2025 | Auvelity |
| Tris Pharma INC | $398.17 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $389.97 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $367.94 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $247.51 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $243.67 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $222.82 | 2019-2025 | Spravato |
| Almatica Pharma LLC | $216.48 | 2024-2025 | Loreev Xr |
| Harmony Biosciences LLC | $193.54 | 2023-2024 | Wakix |
| Idorsia Pharmaceuticals US INC | $172.18 | 2023-2025 | Quviviq, Quviviq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $166.21 | 2022-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $153.72 | 2020-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $144.52 | 2020-2024 | Adzenys Xr-Odt |
| Allergan, INC. | $116.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $112.12 | 2024-2025 | Cobenfy |
| Eisai INC. | $110.35 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $88.38 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $87.97 | 2020-2024 | Hetlioz, Fanapt |
| Shire North American Group INC | $84.38 | 2019 | |
| Bausch Health US, LLC | $70.78 | 2019-2023 | Aplenzin |
| Adlon Therapeutics L.P. | $46.63 | 2019-2021 | |
| Noven Therapeutics, LLC | $44.49 | 2024-2025 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $43.52 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $27.86 | 2019 | |
| Neuronetics, INC. | $20.87 | 2019 | |
| Owp Pharmaceuticals, INC. | $17.64 | 2019 | |
| Merck Sharp & Dohme LLC | $11.93 | 2022 | |
| Neurocrine Biosciences, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Asper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.